The 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines are being applied to HIV-infected patients but have not been validated in this at-risk population, which is known to have a high prevalence of subclinical high-risk morphology (HRM) coronary atherosclerotic plaque. Results: Among all subjects, 10-year atherosclerotic cardiovascular disease (ASCVD) risk score was 3.3% (1.6, 6.6), yet 36% of subjects had HRM coronary plaque. Among those with HRM coronary plaque, statins would be recommended for 26% by 2013 guidelines versus 10% by 2004 guidelines (P ¼ 0.04). Conversely, among those without HRM coronary plaque, statins would be recommended for 19% by 2013 guidelines versus 7% by 2004 guidelines (P ¼ 0.005). In multivariate modeling, while 10-year ASCVD risk score related to HRM coronary plaque burden (P ¼ 0.02), so too did other factors not incorporated into 2013 guidelines.
Results: Among all subjects, 10-year atherosclerotic cardiovascular disease (ASCVD) risk score was 3.3% (1.6, 6.6), yet 36% of subjects had HRM coronary plaque. Among those with HRM coronary plaque, statins would be recommended for 26% by 2013 guidelines versus 10% by 2004 guidelines (P ¼ 0.04). Conversely, among those without HRM coronary plaque, statins would be recommended for 19% by 2013 guidelines versus 7% by 2004 guidelines (P ¼ 0.005). In multivariate modeling, while 10-year ASCVD risk score related to HRM coronary plaque burden (P ¼ 0.02), so too did other factors not incorporated into 2013 guidelines.
Conclusion:
The 2013 ACC/AHA cholesterol guidelines recommend statin therapy for a higher percentage of subjects with and without HRM coronary plaque relative to 2004 guidelines. However, even by 2013 guidelines, statin therapy would not be recommended for the majority (74%) of HIV-infected subjects with subclinical HRM coronary plaque. Outcome studies are needed to determine the utility of new statin recommendations and the contribution of HRM coronary plaque to CVD events among HIVinfected subjects.
Background
In November 2013, the American College of Cardiology/American Heart Association (ACC/AHA) released a Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults [1] . This guideline replaced the Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III -or ATP III -guideline), last updated in 2004 [2] . Cholesterol treatment guidelines such as these, designed for the general population, are typically extrapolated to HIV-infected patients. However, among HIV-infected patients, unique factors relating to infection, treatment, and the body's immune response may contribute to cardiovascular disease (CVD) risk [3] [4] [5] . In addition, studies show that HIV-infected patients have more high-risk coronary plaque [6, 7] [8] , but specific data in the HIV population have not been obtained.
Since the release of the 2013 ACC/AHA guidelines, use of the 10-year ASCVD risk score to determine recommendations for statin therapy has come under scrutiny. When applied to selected primary prevention cohorts, the calculator appears to overestimate observed CVD events by 75-150% [9] . However, the 2013 ASCVD risk calculator may underestimate risk among groups of patients -including HIV-infected patients -in whom atherosclerosis is driven, in part, by nontraditional CVD risk factors. Authors of the guidelines suggest that for individuals outside designated statin benefit groups who are nevertheless considered to be at high risk for CVD, noninvasive cardiac imaging studies may provide useful additional data to consider [1] .
Our research group and others have employed noninvasive contrast-enhanced coronary computed-tomography angiography (CCTA) to characterize prevalence and morphology of subclinical coronary atherosclerosis among HIV-infected patients without clinical CVD. We and others have previously published that HIV-infected patients have more noncalcified coronary plaque [6, [10] [11] [12] and highrisk morphology (HRM) coronary plaque [7] than matched non-HIV controls. HRM coronary plaque may be marked by low attenuation (low density compatible with a necrotic lipid core) and/or positive remodeling (dilation of vessel at plaque site), and these features suggest vulnerability to rupture [13] . Importantly, noncalcifiedand HRM coronary plaque predict CVD events in the general population [14, 15] . Detailed information on coronary plaque morphology may be more useful than coronary artery calcium score for predicting plaque rupture and ensuing MI -particularly if accrued calcification stabilizes individual high-risk coronary plaques, as suggested by recent studies [16, 17] .
In [6, 10] and HRM coronary plaque [7] among men, and on subclinical atherosclerosis among women [11] . Analyses comparing application of 2013 and 2004 cholesterol treatment guidelines among this cohort have never before been reported.
Assessment of historical data, body composition, and metabolic and immunologic parameters Methods for collecting historical/body composition data and for determining levels of metabolic and immune parameters are as per published reports [6, 7, 10, 11] . Multidetector row contrast-enhanced coronary computed-tomography angiography A 64-slice computed tomography (CT) scanner (Sensation 64; Siemens Medical Solutions, Forchheim, Germany) was used to obtain contrast-enhanced coronary CT angiograms for research purposes, as per published reports [6, 7, 10, 11] .
Assessment of subclinical high-risk morphology coronary atherosclerotic plaque by coronary computed-tomography angiography Coronary arterial segments previously identified as having plaque were re-evaluated by trained experts (M.T.L, B.W., S.A.). Low-attenuation plaque was defined as plaque with a mean minimal attenuation less than 40 Hounsfield Units [18] . Positive remodeling was defined as plaque segment diameter/normal reference segment diameter more than 1.05 [18] . Methods for assessing HRM features are as per published reports [7] . Wilcoxon test, and dichotomous data by x 2 test. Spearman's rho was used to evaluate the relationship between 2013 10-year ASCVD risk score and burden of subclinical HRM coronary atherosclerotic plaque (defined as number of high-risk features in the highestrisk coronary plaque). Multivariate linear regression modeling for HRM coronary plaque burden as the dependent variable was performed. Independent variables entered into the model were 10-year ASCVD risk score as well as other parameters, which tended to be different between patients with/without HRM coronary plaque (P value threshold <0.15) and which were not represented in the 10-year ASCVD risk score.
Statistical analysis

Results
Baseline demographics
Baseline demographic and clinical characteristics of the whole group are presented in Table 1 . Among the entire group, 45% (49/108) had coronary atherosclerotic plaque and 36% (39/108) had HRM coronary plaque. (Fig. 1b) (Supplemental Table 1 , http://links.lww.com/QAD/A539).
Comparison of demographic and clinical characteristics of patients for whom statins would/would not be recommended according to 2013 American College of Cardiology/American Heart Association guidelines By 2013 guidelines, those for whom statins would be recommended (versus those for whom statins would not be recommended) tended to be older with higher 10-year Framingham and ASCVD risk scores. Those for whom statins would be recommended also had a longer duration of time since HIV diagnosis, a higher CD4 count, and higher levels of the circulating monocyte activation marker soluble CD163. Among those for whom statins would be recommended, there was also a greater prevalence of diabetes and antihypertensive medication use. There was no statistically significant between-group difference in presence of HRM coronary atherosclerotic plaque ( Table 2) .
Comparison of demographic and clinical characteristics of patients with and without subclinical high-risk morphology coronary atherosclerotic plaque Patients with HRM coronary plaque (versus those without) tended to be older, with higher blood pressure, triglyceride levels, and 10-year Framingham and ASCVD risk scores. The group with HRM coronary plaque (versus the group without) featured a higher percentage of males and individuals of non-Hispanic ethnicity. The percentage of patients in the HRM coronary plaque group with a family history of premature CHD tended to be higher, although the difference was not statistically significant. Additionally, patients in the HRM coronary plaque group tended to have a longer duration of ARTuse and higher viral load, although these differences were not statistically significant (Table 3) .
Relationship between 2013 10-year atherosclerotic cardiovascular disease risk score and high-risk morphology coronary plaque burden Ten-year ASCVD risk score was related to HRM coronary plaque burden on univariate analysis (rho ¼ 0.36, P ¼ 0.0007). In multivariate linear regression modeling for HRM coronary plaque burden, 10-year ASCVD risk score remained significant (P ¼ 0.02) when controlling for ethnicity, family history of premature CHD, duration of ART use, and viral load. Ethnicity, family history, and duration of ARTuse also remained significant in modeling for HRM coronary plaque burden (Table 4) .
Discussion
In this study, we compare for the first time statin recommendations according to 2004 versus 2013 cholesterol treatment guidelines among a cohort of HIV-infected patients without clinical CVD for whom CCTA data on presence or absence of HRM coronary atherosclerotic plaque are available. We find that by 2013 ACC/AHA guidelines (versus 2004 guidelines), statins would be recommended for more patients with and without HRM coronary plaque. And yet, statins would not be recommended for the majority of patients with HRM coronary plaque. Traditional CVD risk factors encompassed in the 2013 10-year ASCVD risk score relate to HRM coronary plaque burden, but so too do other factors, both traditional (e.g., family history) and HIV-specific (duration of ART use) not encompassed in the guidelines.
The 2013 ACC/AHA cholesterol treatment guidelines aim to accurately identify individuals for whom statin therapy would meaningfully reduce the risk of incurring a CVD event. HIV-infected patients, when compared with uninfected controls, face a 1.5 to 2-fold heightened MI risk [19] [20] [21] and 1.5-fold heightened stroke risk [22] . 2013 guidelines suggest that for populations with perceived high CVD risk for whom statins are not recommended, additional clinical information, where available, should be considered. Leveraging a cohort of HIV-infected patients without known CVD who have undergone CCTA, we analyzed recommendations for statin therapy according to 2013 ACC/AHA guidelines in relation to the presence or absence of any plaque and of HRM coronary atherosclerotic plaque. In the general population, the presence of HRM coronary plaque predicts a markedly increased risk of incident CVD. Motoyama et al. showed that among 1059 patients evaluated for 27 AE 10 months, those with no coronary atherosclerotic plaque and those with plaque absent HRM features incurred ACS at rates of 0% and 0.5%, respectively. In contrast, those with coronary plaque characterized by one or two HRM features incurred ACS at rates of 3.7 and 22.2%, respectively [15] . HIV-infected patients, relative to non-HIV controls, have a higher prevalence and burden of HRM coronary plaque [7] , but whether this observation underlies increased CVD risk in HIV is unknown. Of note, in the general population, statin therapy has been shown to stabilize HRM plaque features [23, 24] . Such stabilization, which may be mediated through LDL-lowering effects and/or through pleiotropic immune-modulatory effects, is presumed to reduce plaque vulnerability to rupture. Whether HIV-infected patients with subclinical HRM coronary atherosclerotic plaque face an unacceptably high risk of incurring a CVD event -specifically MI -and would potentially benefit from statin therapy is unknown.
Cholesterol guidelines in HIV
When applied to our cohort, 2013 ACC/AHA guidelines (versus 2004 guidelines) increased by roughly 2.5-fold the number of patients for whom statins would be recommended, but the percentage of patients for whom statins would be recommended remained low even under the new guidelines. Increased percentages of patients for whom statins would be recommended were noted in both the subgroups with and without subclinical HRM coronary atherosclerotic plaque. Importantly, in our cohort, although 2013 ACC/AHA guidelines generally increased the number of patients for whom statins would be recommended, statin therapy would not be recommended for the majority (74%) of HIV-infected patients with HRM coronary plaque.
Our analyses provide insights as to why, according to the current guidelines, statin therapy might not be recommended for HIV-infected patients with subclinical HRM coronary atherosclerotic plaque. In our cohort, patients with HRM coronary plaque tended to be young (15% under age 40), with low LDL levels (100 AE 30 mg/dl). Thus, in this subgroup, even though the prevalence of selected traditional CVD risk factors like smoking (54%) was high, cumulative traditional CVD risk as estimated by the 2013 10-year ASCVD risk score (5.5%) was low. That relatively young HIV-infected patients with low LDL levels may still face heightened MI risk is supported by Freiberg's analysis of data from 82 459 patients in the Veterans Aging Cohort Study. In this large cohort, although 46.4% of HIV-infected patients had LDL cholesterol levels less than 100 mg/dl, HIV-infected patients (versus non-HIV controls) had higher relative incidence rates of acute MI across all age groups, and particularly in the 30 to 39-year-old group [21] .
Our data suggest that the 2013 10-year ASCVD risk score encompasses some but not all potential risk factors for the development of HRM coronary atherosclerotic plaque Nevertheless, our study takes into consideration new knowledge about the pathophysiology of atherosclerosis among HIV-infected patients and furnishes novel insights on the potential for even 2013 ACC/AHA guidelines to underestimate CVD risk in HIV. An event-driven randomized controlled trial of statin therapy in HIV would definitively determine baseline factors predictive of CVD in this population and identify subgroups of HIV-infected individuals most likely to substantially benefit from statin therapy. 
